Publications
46
Citations
79
Est. group size
—
Recurring co-author estimate
Active years
6
Publishing since 2021
Aastha Dhakal's work focuses on cancer outcomes research, using large patient datasets to study survival, prognostic factors, and treatment effects in cancers such as bladder (urothelial), endometrial, blood cancers (leukemia), and the effects of immunotherapy on secondary cancer risk. This research is largely retrospective and clinical, aiming to describe real-world patient outcomes and identify factors linked to prognosis and treatment response.
Publication output was minimal or absent before 2021 but has grown sharply since then, especially from 2024 to 2026, indicating a recent and rapidly increasing rate of research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
Clinical Cancer Research · 2026
- Real-World Survival Outcomes and Prognostic Factors in De Novo Stage IV Urothelial Bladder Cancer: A 13-Year Retrospective Cohort Study
Clinical Genitourinary Cancer · 2026
- Supplementary Methods S1 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Supplementary Table S3 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Supplementary Methods S2 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Supplementary Figure S2 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Supplementary Table S7 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Supplementary Table S11 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Supplementary Figure S1 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Supplementary Table S1 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Supplementary Table S2 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Supplementary Table S6 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Supplementary Table S9 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Supplementary Table S8 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Supplementary Table S4 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
- Journal of Clinical Oncology×10
- Blood×6
- International Journal of Radiation Oncology*Biology*Physics×3
- Nature Communications×1
- Cancer Biology & Therapy×1
- Asrar Alahmadi
Medicine · The Ohio State University
- Songzhu Zhao
Medicine · The Ohio State University
- Lai Wei
Medicine · The Ohio State University
- Jing Liang
Medicine · The Ohio State University
- Kai He
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile